Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,775 total articles

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

Ernexa Therapeutics announced preclinical data demonstrating that their lead cell therapy candidate ERNA-101, combined with PD-1 blockade, achieved complete tumor clearance and 100% survival in ovarian cancer mouse models. This novel therapy remodels the tumor microenvironment from immunosuppressive to immune-activated, enhancing the efficacy of ch…

Global Mofy’s U.S. Subsidiary Eaglepoint AI Selected for NVIDIA Inception Program, Further Strengthening Its Global AI Infrastructure Services Layout

Global Mofy’s U.S. Subsidiary Eaglepoint AI Selected for NVIDIA Inception Program, Further Strengthening Its Global AI Infrastructure Services Layout

Global Mofy AI Limited (Nasdaq: GMM) announced that its U.S. subsidiary Eaglepoint AI Inc. was selected for the NVIDIA Inception Program. This inclusion recognizes Eaglepoint AI's strengths in scalable AI training workflows and high-quality data infrastructure services, and supports Global Mofy's expansion into deeper AI infrastructure and model su…

Upexi Provides Periodic Update to its Share Repurchase Program

Upexi Provides Periodic Update to its Share Repurchase Program

Upexi, Inc., a Solana-focused digital asset treasury and consumer brands company, provided an update on its $50 million authorized share repurchase program announced in November 2025. As of May 5, 2026, the company has repurchased approximately 2.89 million shares, spending around $2 million, leaving over $47 million available for future repurchase…

FangDD Files 2025 Annual Report on Form 20-F

FangDD Files 2025 Annual Report on Form 20-F

FangDD Network Group Ltd., a China-based property technology company listed on NASDAQ, has filed its annual report for the fiscal year ended December 31, 2025, with the U.S. SEC. The report includes audited consolidated financial statements and is available on the company's investor relations website.

Giftify’s CardCash Reports Enhanced Fraud Detection Driving Stronger Approved Order Volume in Q1 2026

Giftify’s CardCash Reports Enhanced Fraud Detection Driving Stronger Approved Order Volume in Q1 2026

Giftify, Inc. reports significant enhancements in CardCash.com's fraud detection systems resulting in a 56% reduction in fraud-related declines year-over-year for Q1 2026. This improvement has led to over 100,000 customer orders approved with approval rates exceeding 96%, increased transaction efficiency, and stronger platform performance. The comp…

Innventure Receives Letter of Support from Ascent Capital Partners

Innventure Receives Letter of Support from Ascent Capital Partners

Innventure, Inc., an industrial growth conglomerate listed on NASDAQ under the ticker INV, announced that Ascent Capital Partners has amended its SEC Schedule 13D filing to include a letter expressing strong support for Innventure's leadership and strategic direction. This endorsement underscores investor confidence in Innventure's approach to buil…

StepStone Group and PitchBook Announce Partnership to Deliver Deal-Level Performance & Operating Metrics to Private Market Participants

StepStone Group and PitchBook Announce Partnership to Deliver Deal-Level Performance & Operating Metrics to Private Market Participants

StepStone Group and PitchBook, a Morningstar company, have entered into a partnership to integrate StepStone's proprietary deal-level benchmarks into the PitchBook platform. This collaboration aims to provide private market participants—including fund managers and investors—with advanced, granular analytics and benchmarking tools that improve trans…

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Scienture Holdings announced that the USPTO has granted a third patent for ARBLI™ (losartan potassium) oral suspension, the first FDA-approved ready-to-use liquid losartan formulation. This patent extends market exclusivity through 2041, strengthening ARBLI™'s position in the $241 million U.S. losartan market with 72 million prescriptions annually.…